In HIV-infected patients on ART, which laboratory tests should be monitored regularly besides viral load and CD4 count?

• A. Comprehensive metabolic panel (liver enzymes with ART metabolism), lipid profile, renal function, CBC
• B. Lipid profile only
• C. Renal function only
• D. CBC only

Answer: (A)

Regular monitoring for people on ART isn’t just about whether the virus is kept in check; it’s about catching treatment-related toxicities and metabolic changes early so therapy stays safe and effective. A comprehensive metabolic panel provides a broad view of how the liver and kidneys are functioning, since many antiretroviral drugs are processed by these organs. Seeing how liver enzymes and kidney values are behaving helps identify hepatotoxicity or nephrotoxicity before they cause symptoms.

Adding a lipid profile is important because some ART regimens can raise cholesterol and triglycerides. Detecting dyslipidemia early allows timely interventions to reduce cardiovascular risk, which remains a long-term concern for people living with HIV on ART.

Monitoring renal function specifically is essential because certain drugs have known nephrotoxic potential or require dose adjustments based on kidney performance. Keeping an eye on kidney function helps prevent drug accumulation and related toxicity.

A complete blood count screens for anemia and other blood cell abnormalities that can arise with some antiretrovirals. Early detection of hematologic effects supports safer prescribing and timely changes if needed.

Together, these tests give a well-rounded safety net: liver and kidney health, blood cell status, and metabolic risk, complementing viral load and CD4 count to guide ongoing treatment.